Magnesium Sulfate CRI

Physiologic calcium antagonist. Competes with calcium at voltage-gated calcium channels (slow inward current), NMDA receptors, and ATPase binding sites. In cardiac tissue: slows AV conduction, prolongs refractoriness, decreases automaticity, the mechanism underlying its utility in VT, torsades de pointes, and refractory VPCs. Also stabilizes neuromuscular function (loss of patellar reflex with elevated serum levels) and produces mild bronchodilation. Renal elimination, with accumulation in renal failure.

Open calculator →

Clinical background

Magnesium sulfate is used in the vet ICU as an antiarrhythmic adjunct, primarily for ventricular tachyarrhythmia that is refractory to first-line agents, for torsades de pointes when this rare rhythm appears, and for replacement therapy in patients with documented or strongly suspected hypomagnesemia. Magnesium occupies an unusual place in the cardiology toolkit: it is a physiologic ion that the patient may already be deficient in, and replacement alone can suppress the rhythm; at higher infusion rates it produces a more pharmacologic antiarrhythmic effect through direct membrane and ion-channel actions. The clinical pivot is matching the rate of administration to the goal. Slow replacement for true deficiency, faster infusion for active arrhythmia treatment.

Pharmacology

Magnesium is a divalent cation with broad physiologic roles, including:

• Cofactor for Na/K ATPase, which maintains the resting membrane potential. Hypomagnesemia indirectly produces hypokalemia by impairing renal K conservation; correcting Mg often corrects refractory K depletion when potassium supplementation alone has failed.
• Direct effect on the slow inward calcium current at the cardiac cell membrane, slowing AV-nodal conduction and reducing automaticity at higher concentrations.
• NMDA receptor blockade at higher concentrations, which is the mechanism behind its use in eclampsia and seizure-prevention in human medicine. Vet relevance is mainly the implication for refractory seizures, where adjunct Mg has been described.
• Neuromuscular junction effect: Mg competitively inhibits presynaptic calcium-dependent acetylcholine release. At high serum concentrations this produces the weakness, hyporeflexia, and (at very high concentrations) respiratory paralysis that limits the safe upper bound.

Onset is rapid after IV bolus (minutes) and is sustained as long as the infusion runs. The half-life in plasma is variable but the clinical effect of a CRI tracks the steady-state level it produces. Renal excretion is the principal clearance route; renal dysfunction is the most important factor predisposing to magnesium accumulation and toxicity.

Indications

Primary use cases:

• Refractory ventricular tachyarrhythmia when first-line agents (lidocaine in dogs, sotalol or amiodarone in some protocols) have not produced rhythm control. Magnesium is often effective as an adjunct in this setting; the patient may have an underlying hypomagnesemia driving the rhythm.
• Torsades de pointes, the prolonged-QT polymorphic VT. Rare in dogs and cats but, when it appears, magnesium is the first-line treatment regardless of Mg level. 25–50 mg/kg IV slowly is the typical loading dose, followed by CRI.
• Hypomagnesemia replacement in patients with documented or strongly suspected deficiency (refractory hypokalemia, malabsorption, prolonged diuretic use, alcohol-toxicity in dogs). Slower infusion rate, longer duration; the goal is replenishment rather than acute pharmacologic effect.
• Premature ventricular complexes (VPCs) in critically ill patients, particularly when adrenergic-driven and when Mg level is low or unknown.
• Tetanus and other hypertonic states at high doses, exploiting the neuromuscular-junction effect. Vet use is uncommon but reported.

Magnesium is not a substitute for definitive antiarrhythmic therapy where one exists (lidocaine for VT in dogs, esmolol for SVT). It is an adjunct and a replacement; it is also the only therapy for torsades.

Dosing

• Dogs, antiarrhythmic CRI: 5–50 mg/kg/hr (of magnesium sulfate), titrated against rhythm response and clinical effect.
• Cats, antiarrhythmic CRI: 5–50 mg/kg/hr; some references suggest a more conservative upper bound (around 25 mg/kg/hr) given cat renal sensitivity. The Plumb’s range is the same for both species.
• Caution above: 30 mg/kg/hr in dogs, 25 mg/kg/hr in cats. Hypotension and AV-block risk rise above these thresholds, and the marginal antiarrhythmic benefit of going higher is limited.
• Loading dose for ventricular arrhythmia: 25–50 mg/kg IV slowly over 5–10 minutes.
• Loading dose for torsades: 25–50 mg/kg IV slowly over 1–2 minutes, with continuous ECG and BP. Faster delivery is appropriate because the rhythm is immediately life-threatening.

The dose is in milligrams of magnesium sulfate (the salt), not elemental magnesium. 50% magnesium sulfate (500 mg/mL) is the stock. 1 g of magnesium sulfate contains approximately 100 mg of elemental Mg (8.1 mEq). Most vet references and the InfusionFox calculator express the dose in mg of the salt for consistency with how clinicians read the vial label.

Cat dosing tends to start at the lower end of the range (5–10 mg/kg/hr) and titrate up. Renal function dictates the upper bound; in patients with reduced GFR, accumulation can produce hypermagnesemia faster than the published range suggests.

Administration

Stock concentration in the US is 500 mg/mL (50% magnesium sulfate), typically a 50 mL multi-dose vial. For CRI delivery the stock is diluted into 0.9% sodium chloride or 5% dextrose. The InfusionFox calculator preselects three weight-banded preparations (100, 50, or 25 mg/mL) to keep the pump rate in the precision range.

Compatibility is broad. Do not mix in the same line with calcium-containing solutions (precipitates as calcium-magnesium salts), sodium bicarbonate (precipitates as magnesium carbonate), or phosphate-containing fluids (precipitates as magnesium phosphate).

Magnesium sulfate is stable at room temperature and does not require light protection. A loading bolus given too quickly can produce transient hypotension and flushing; the rate matters even more than the dose.

Drug interactions

• Calcium channel blockers (diltiazem, amlodipine, verapamil) have additive effects with magnesium on AV-nodal conduction and vascular smooth muscle. AV block grade and hypotension risk both rise; co-administration is acceptable but warrants closer monitoring.
• Beta-blockers (esmolol, propranolol) have additive AV-nodal slowing. The combination is sometimes deliberate in catecholamine-driven arrhythmia management; watch for excessive bradycardia or AV block.
• Digoxin: hypomagnesemia potentiates digoxin toxicity. Correcting Mg often improves digoxin-related arrhythmia.
• Aminoglycosides and neuromuscular blockers have additive effects on the neuromuscular junction. Severe weakness or respiratory depression can result; if a patient is on neuromuscular blockade or recently received an aminoglycoside, magnesium should be used cautiously.
• Diuretics (loop, thiazide) accelerate urinary Mg loss; patients on long-term diuretic therapy frequently have hypomagnesemia and are candidates for replacement.

Adverse effects

• Hypotension, particularly during loading or at higher CRI rates. Usually correlates with rate of administration; slowing the bolus or reducing the infusion rate resolves it.
• AV-block (any grade), more common above 30 mg/kg/hr or in patients with concurrent calcium channel blockers or beta-blockers.
• Neuromuscular weakness in patients with renal dysfunction or those approaching hypermagnesemia. Patellar reflex depression is the earliest bedside sign and is described in human medicine as the most reliable clinical indicator that serum Mg has reached the upper safe range. The reflex is easy to test in dogs and cats and is worth checking every 2–4 hours during sustained CRI.
• Respiratory depression at high serum Mg, through the same neuromuscular-junction effect. Ventilatory support may be needed; reversal is calcium gluconate IV.
• Hypocalcemia with prolonged infusion; the ionic competition at protein-binding sites reduces ionized calcium. Clinically meaningful in long infusions and in patients already at risk (eclampsia, post-thyroid surgery).
• Local irritation at the infusion site at higher concentrations; the dilute preparations (25 or 50 mg/mL) are well tolerated.

Monitoring

• Continuous ECG for rate, rhythm, AV-block grade, and QT-interval changes. The goal in antiarrhythmic use is rhythm correction; PR-interval prolongation is expected and acceptable, advancing AV-block grade is not.
• Continuous or frequent blood pressure, particularly during loading and at higher CRI rates.
• Patellar reflex every 2–4 hours during sustained CRI. A depressed or absent patellar reflex is the bedside flag that serum Mg has reached the upper end of the therapeutic range; recheck level, consider reducing the dose.
• Serum magnesium every 12–24 hours during prolonged CRI, more frequently in patients with renal dysfunction. The target range for active antiarrhythmic therapy is the upper end of normal to mildly elevated; sustained hypermagnesemia is the toxicity setting.
• Serum calcium and potassium at intervals; both can fall during prolonged Mg therapy and both may need replacement.
• Renal function (BUN, creatinine, urine output) at intervals; renal dysfunction is the principal predisposing factor for accumulation.

Reversal of toxicity

If hypermagnesemia produces clinically significant neuromuscular weakness, AV block, or respiratory depression: stop the infusion, support ventilation as needed, and administer calcium gluconate (0.5–1.5 mL/kg of 10% calcium gluconate IV slowly over 10–20 minutes, with continuous ECG). Calcium directly antagonizes the neuromuscular-junction effect of magnesium and reverses the weakness and bradycardia within minutes.

Renal replacement therapy is the definitive treatment for severe hypermagnesemia in anuric patients, but is rarely available in vet practice.

Sources

• Plumb’s Veterinary Drugs, magnesium sulfate monograph (current edition).
• Bateman SW. Disorders of Magnesium. In: DiBartola SP, ed. Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. 4th ed. Elsevier; 2012:212–229. Chapter 9. (Mg physiology, replacement strategy, and dosing.)
• Macintire DK, Drobatz KJ, Haskins SC, Saxon WD. Manual of Small Animal Emergency and Critical Care Medicine. 2nd ed. Wiley-Blackwell; 2012. (Antiarrhythmic use in ICU and CRI dosing.)
• 2024 ACVIM Consensus Statement on cardiac arrhythmias (where applicable to magnesium use; reference for current vet recommendations on torsades and refractory VT management).